AVNR

Avanir Pharmaceuticals, Inc. Press Releases

$3.46
*  
0.04
 negative 
1.17%
Get AVNR Alerts
*Delayed - data as of Apr. 17, 2014 
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Pharma Stocks on our Radar -- Research on AVANIR Pharma, Zoetis, Salix Pharma, and Jazz Pharma
4/10/2014 12:31:00 PM - PR Newswire

Avanir Pharmaceuticals Announces Acceptance of New Drug Application for AVP-825 for the Acute Treatment of Migraine
3/26/2014 9:00:00 AM - PR Newswire

Pharmaceutical Equities under Review -- Research on Zoetis, Mylan, AVANIR Pharma and Actavis
3/21/2014 11:11:00 AM - PR Newswire

Avanir Pharmaceuticals Announces Publication of Research Showing Dextromethorphan has Antidepressant-like Effects In Vivo
3/20/2014 9:00:00 AM - PR Newswire

Avanir Pharmaceuticals Announces Appointment of Mark Corrigan to Board of Directors
3/19/2014 4:00:00 PM - PR Newswire

Avanir Pharmaceuticals Presents Data from a Benchmark Study of PBA Symptoms in Veterans with Mild Traumatic Brain Injury
3/19/2014 9:00:00 AM - PR Newswire

Avanir Pharmaceuticals to Participate in Two Conferences in March
2/28/2014 9:00:00 AM - PR Newswire

Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2/7/2014 4:00:00 PM - PR Newswire

Avanir Pharmaceuticals Reports Fiscal 2014 First Quarter Financial And Business Results
2/5/2014 4:00:00 PM - PR Newswire

New Drug Application Submitted for Migraine Treatment Using OptiNose Technology
1/30/2014 9:25:00 AM - PR Newswire

Avanir Pharmaceuticals Announces Submission of New Drug Application for AVP-825 for the Acute Treatment of Migraine
1/30/2014 9:00:00 AM - PR Newswire

Avanir Pharmaceuticals Announces Date of Fiscal 2014 First Quarter Financial Results and Conference Call
1/28/2014 8:30:00 AM - GlobeNewswire